Neovacs Addresses Rumors About PXT3003

On April 16, 2025, Neovacs, a biopharmaceutical company, addressed rumors surrounding PXT3003, a drug candidate for Charcot-Marie-Tooth disease type 1A. This drug was originally developed by Pharnext, which had licensed the drug for China to a joint venture majority-owned by Tasly. Recently, it was reported that Tasly has applied for marketing authorization in China for this drug. Neovacs cannot currently confirm this information but is in contact with its Chinese partner for clarification.

If approved in China, PXT3003 could benefit Neovacs' assets and potentially support approval applications in other markets. However, the company emphasizes the uncertainty surrounding the outcome of this procedure, having already recorded a full provision for the claim in its accounts by mid-2024.